Legend reveals its hold stems from insufficient IND info; Provention re-files BLA after July CRL
In its fourth quarter and full year report, Legend Biotech went into a little more detail as to why the FDA slapped it with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
